Cell & Gene Therapy - Informa Connect

@CellTherapyIC

The official account for the Informa Connect Cell & Gene Therapy series, featuring the latest events, content and training

London
Vrijeme pridruživanja: ožujak 2012.

Tweetovi

Blokirali ste korisnika/cu @CellTherapyIC

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CellTherapyIC

  1. In this piece, authors discuss the use of analytical assays in process development and manufacturing of cell and gene therapies

    Poništi
  2. The future is bright for antibody-based & cellular immunotherapies, with the technologies of bispecifics and CAR-Ts converging. This whitepaper looks at the latest advances & challenges in immuno-oncology drug development

    Poništi
  3. Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges, and the latest for therapies in this exclusive interview

    Poništi
  4. CAR-T and T-cell receptor therapies are some of the most exciting emerging therapies on the market today. This whitepaper discusses recent developments in CAR and TCR and the overlap with engineering

    Poništi
  5. How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  6. When developing a new therapy how do you keep in complete control of its manufacturing? This whitepaper looks at what to consider - whatever path you take.

    Poništi
  7. 62% of respondents their cell and therapies both internally and externally

    Poništi
  8. Heidelberg-based have created tumor-targeted oncolytic virus vaccines using encoded bispecific T-cell engagers. In this recorded webinar, Christine Engeland, MD, PhD explains their journey.

    Poništi
  9. The high costs of cell therapy puts it out of reach for many cancer patients. How can it be made more affordable? We asked three industry experts

    Poništi
  10. In this exclusive interview founder Jon Rowley explores the decision making process for choosing a manufacturing platform for cell therapies, and how that impacts COGS

    Poništi
  11. Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges, and the latest for therapies in this exclusive interview

    Poništi
  12. Chris Gemmiti, VP of Operations discusses the highs and lows of mesenchymal and whether their peak is yet to come. Read more

    Poništi
  13. The future is bright for antibody-based & cellular immunotherapies, with the technologies of bispecifics and CAR-Ts converging. This whitepaper looks at the latest advances & challenges in immuno-oncology drug development

    Poništi
  14. Can viruses be used to create tumor-targeted vaccines? In an on-demand webinar, Christine Engeland, MD, PhD explains how they have done just that, by encoding bispecific T-cell engagers within measles virus vectors.

    Poništi
  15. Autologous cell therapies carry several challenges to commercialization, including high costs, the risks of manual processing, and compliance with strict timelines. This eBook presents two perspectives on addressing these challenges

    Poništi
  16. Where do you start in setting up manufacturing for a new therapy? Insourcing or outsourcing - and when is best to decide? This whitepaper presents best practices and case studies.

    Poništi
  17. 62% of respondents their cell and therapies both internally and externally

    Poništi
  18. Gene therapies could revolutionize treatment of genetic disease, but how should the cost-effectiveness of these drugs be measured? We explore ->

    Poništi
  19. Knud Jensen, Professor, Department of Chemistry at , discusses how can academia and biotechs can work better together to both benefit

    Poništi
  20. Autologous cell therapies carry several challenges to commercialization, including high costs, the risks of manual processing, and compliance with strict timelines. This eBook presents two perspectives on addressing these challenges

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·